Transient Expression of GATA3 in Hematopoietic Stem Cells Facilitates Helper Innate Lymphoid Cell Differentiation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 15 11 2018
accepted: 26 02 2019
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 4 9 2020
Statut: epublish

Résumé

Helper Innate lymphoid cells (ILCs) are tissue resident lymphocytes that play a critical role in a number of biological processes. Several transcription factors are required for the differentiation of hematopoietic stem cells (HSCs) into ILCs. Recent studies demonstrate GATA3 as a transcriptional regulator that plays an essential role in ILC development. We aimed to modulate the differentiation of human cord blood-derived CD34

Identifiants

pubmed: 30949172
doi: 10.3389/fimmu.2019.00510
pmc: PMC6438154
doi:

Substances chimiques

GATA3 Transcription Factor 0
GATA3 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

510

Subventions

Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI100879
Pays : United States

Références

Immunity. 2003 Dec;19(6):863-75
pubmed: 14670303
Blood. 2006 Dec 1;108(12):3824-33
pubmed: 16902150
Nature. 2009 Feb 5;457(7230):722-5
pubmed: 18978771
J Exp Med. 2009 Jan 16;206(1):35-41
pubmed: 19114665
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Immunol Rev. 2010 Nov;238(1):93-109
pubmed: 20969587
Blood. 2011 Apr 14;117(15):4052-5
pubmed: 21310921
Nat Immunol. 2011 Sep 11;12(11):1055-62
pubmed: 21909091
Nat Immunol. 2011 Sep 11;12(10):949-58
pubmed: 21909092
Science. 2012 Apr 6;336(6077):91-5
pubmed: 22383805
J Exp Med. 2012 Apr 9;209(4):729-40
pubmed: 22430492
Immunity. 2012 Aug 24;37(2):339-50
pubmed: 22921121
Immunity. 2012 Oct 19;37(4):649-59
pubmed: 23063330
Immunity. 2012 Oct 19;37(4):634-48
pubmed: 23063333
Blood. 2013 Mar 21;121(12):2234-43
pubmed: 23327921
Nature. 2013 Feb 14;494(7436):261-5
pubmed: 23334414
Nat Immunol. 2013 Mar;14(3):221-9
pubmed: 23334791
Immunity. 2013 Apr 18;38(4):769-81
pubmed: 23453631
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10240-5
pubmed: 23733962
J Exp Med. 2014 Feb 10;211(2):199-208
pubmed: 24419270
Nature. 2014 Apr 17;508(7496):397-401
pubmed: 24509713
J Virol. 2014 May;88(10):5877-80
pubmed: 24600007
Immunity. 2014 Mar 20;40(3):378-88
pubmed: 24631153
Cell. 2014 Apr 10;157(2):340-356
pubmed: 24725403
Blood. 2014 Jul 31;124(5):812-21
pubmed: 24855210
Immunity. 2014 Sep 18;41(3):354-365
pubmed: 25238093
Immunity. 2014 Dec 18;41(6):988-1000
pubmed: 25500367
Cell Rep. 2015 Mar 31;10(12):2043-54
pubmed: 25801035
Nat Immunol. 2015 Jun;16(6):599-608
pubmed: 25915732
J Exp Med. 2015 Jun 1;212(6):875-82
pubmed: 25964370
Nat Rev Immunol. 2015 Jul;15(7):415-28
pubmed: 26065585
Nat Commun. 2015 Sep 23;6:8280
pubmed: 26395069
Nature. 2015 Dec 24;528(7583):560-564
pubmed: 26649819
Curr Opin Immunol. 2016 Feb;38:75-85
pubmed: 26707651
Cell Rep. 2016 Oct 4;17(2):436-447
pubmed: 27705792
Cell. 2017 Mar 9;168(6):1086-1100.e10
pubmed: 28283063
J Clin Invest. 2017 May 1;127(5):1813-1825
pubmed: 28375154
Front Immunol. 2017 Mar 27;8:360
pubmed: 28396671
Blood. 2017 Jun 29;129(26):3428-3439
pubmed: 28533309
Front Immunol. 2017 Aug 31;8:1047
pubmed: 28912776
J Exp Med. 2018 Jan 2;215(1):249-262
pubmed: 29183988
Front Immunol. 2017 Nov 14;8:1571
pubmed: 29184556
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344

Auteurs

Dejene M Tufa (DM)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Ashley M Yingst (AM)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Tyler Shank (T)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Seonhui Shim (S)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

George Devon Trahan (GD)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Jessica Lake (J)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Renee Woods (R)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Kenneth L Jones (KL)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Michael R Verneris (MR)

Department of Pediatric Hematology, Oncology and BMT, School of Medicine, University of Colorado, Aurora, CO, United States.
Department of Children's Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH